top of page

ATMP Manufacturing

Price

€1,495.00

This 1.5-day course will be delivered onsite (EU Biotech Campus, Belgium) by NIBRT experts.

 

Understanding Advanced Therapy manufacturing processes is crucial for safe, effective production and regulatory approval. This theoretical course will cover technologies, processes, and regulatory considerations for Advanced Therapy manufacturing.

 

Key topics covered include manufacturing processes for ATMPs, regulatory requirements & GMP Standards for ATMP production. Following an overview of ATMPs and how they differ from traditional biopharma, the lectures will then focus on cell therapies including :

 

  • the endto-end CAR-T manufacturing process from cell sourcing and genetic modification to expansion and formulation
  • Stem cell therapies  
  • autologous vs. allogeneic approaches
  • mRNA manufacturing
  • an overview of QC for cell therapies

 

Day 2 will move on to gene therapies including gene therapy delivery systems and manufacturing platforms including viral vectors, process scale-up and challenges, and QC for gene therapies.

Quantity

Program

Day 1 : 

 

09:00 – 09:30 – Welcome and Introductions
09:30 – 10:30 – Lecture 1: Introduction to Advanced Therapy Medicinal Products
10:30 – 10:45 – Break
10:45 – 11:30 – Lecture 2: Introduction to Cell Therapies
11:30 – 11:45 – Break
11:45 – 12:45 – Lecture 3: CAR-T Manufacturing Process
12:45 – 13:30 – Lunch
13:30 – 14:30 – Lecture 4: Introduction to mRNA
14:30 – 14:45 – Break
14:45 – 15:30 – Lecture 5: An Overview of QC Analytics for Cell Therapy
15:30 – 16:00 – Day 1 Wrap-Up and Q&A

 

Day 2 : 

09:00 – 09:15 – Recap of Day 1
09:15 – 10:00 – Lecture 6: Introduction to Gene Therapies
10:00 – 10:15 – Break
10:15 – 11:00 – Lecture 7: Gene Delivery Systems
11:00 – 11:15 – Break
11:15 – 12:00 – Lecture 8: An Overview of QC Analytics for Gene Therapy
12:00 – 12:15 – Wrap-Up and Feedback
12:15 – 13:00 – Lunch and Course Close

Course Details

  • Date: 14 & 15 October 2025

  • Time: 9:00 AM – 4:00 PM Day 1 | 9:00 AM – 1:00 PM Day 2 

  • Duration: 1.5 days 

  • Format: In-person

  • Trainer: Tadeusz Tazbierski  

  • Location : EU Biotech Campus, 13 Avenue Georges Lemaître 6041, Belgium 

  • Language: English (oral and written)

  • Price: €1495 excl. VAT

  • Evaluation: Yes (including a needs-assessment questionnaire for further training opportunities)

Who Should attend ?

This course is designed for professionals involved in or transitioning into the field of Advanced Therapy Medicinal Products (ATMPs). It is particularly relevant for:

  • Manufacturing Scientists and Engineers working in biopharma or cell/gene therapy production

  • Process Development Scientists focusing on ATMP workflows

  • Quality Assurance (QA) and Quality Control (QC) Professionals in advanced therapies

  • Regulatory Affairs Specialists working with GMP and ATMP compliance

  • R&D Scientists developing or optimizing cell, gene, or mRNA-based therapies

  • Clinical Trial Managers involved in ATMP studies and logistics

  • Biotech Project Managers overseeing ATMP programs

  • Bioprocess Technicians and Associates working in GMP or non-GMP environments

  • Technology Transfer and CMC Experts involved in the scale-up of advanced therapies

  • Healthcare and Hospital Lab Managers dealing with ex-vivo cell therapies

  • Supply Chain and Logistics Professionals supporting ATMP delivery and traceability

  • Academics and Researchers seeking to understand industrial practices in ATMP manufacturing

  • Training Coordinators and Learning & Development Managers in biopharma education

Expert

Tadeusz Tazbierski

Tad Tazbierski completed his Masters degree in Biotechnology at the University of Wrocław. Tad joined the National Institute for Bioprocessing Research and Training (NIBRT) in 2017 as a technician and has since advanced to the role of Senior Trainer, a position he has held for the last three years. With extensive experience in bioprocessing, Tad specializes in the development and implementation of competency-based training programs, ensuring that learners gain practical, hands-on expertise aligned with current industry standards in the areas of upstream processing and cell culture, cell and gene therapies, and cGMP. His contributions at NIBRT support both academic and industry professionals in mastering the latest advancements in biopharmaceutical manufacturing. 

Nathania Harron 

Nathania Harron is currently pursuing a Level 9 qualification in ATMP Vector Manufacturing at Atlantic Technological University (ATU), deepening her expertise in advanced therapeutics. She brings a strong background in cell and gene therapy, with prior experience as a research assistant focused on stem cell applications and three years as a single-cell analysis scientist developing Tumor-Infiltrating Lymphocyte (TIL) therapies. For the past two years, Nathania has been a bioprocess trainer at the National Institute for Bioprocessing Research and Training (NIBRT), where she specialises in downstream processing, quality control (QC) analytics, and training professionals in cutting-edge cell and gene therapy manufacturing techniques. Her work reflects a commitment to advancing biopharmaceutical education and innovation in emerging therapies.

 

bottom of page